MorphoSys AG — Regulatory Filings 2004

Jun 24, 2004

News Details

Corporate | 24 June 2004 07:45

MorphoSys is Granted Patent for CysDisplay(TM) Screening Technology

Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– Martinsried/Munich, June 24, 2004 MorphoSys is Granted Patent for CysDisplay(TM) Screening Technology MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has granted a new patent on its proprietary CysDisplay(TM) screening technology. CysDisplay(TM) is an important component of MorphoSys’s proprietary HuCAL GOLD(R) technology, and the new patent provides additional protection for the same. The new patent (US 6,753,136) entitled “Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds” describes a selection technology based on phage display for selecting high affinity antibodies. Additional patent applications are pending in other jurisdictions around the world. In November 2001 MorphoSys released its most recent and advanced version of the proprietary antibody library, HuCAL GOLD(R). In addition to several significant improvements to the library, CysDisplay(TM) screening technology was also incorporated into the technology. The resulting library, in comparison to previous HuCAL(R) versions and to other phage display based antibody libraries, possesses several unique advantages. One such advantage is the ability to standardize protocols relating to antibody fragment recovery from each screening round, thus making the technology ideally suited for high throughput applications. “The CysDisplay(TM) screening technology is another important addition to our portfolio of antibody library technologies. It contributes significant advantages over previous methods we have employed, and further differentiates our product mix”, commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. About MorphoSys: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company’s proprietary Human Combinatorial Antibody Library (HuCALâ) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Biogen Idec Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Novartis AG (Basel, Switzerland), Oridis Biomed GmbH (Graz/Austria), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). For further information please visit the corporate website at: http://www.morphosys.com/ . Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements” for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company’s proprietary rights and other factors described in the prospectus relating to the company’s recent public offering. For more information, please contact MorphoSys: Dave Lemus Chief Financial Officer Tel: +49 (0) 89 / 899 27-439 Fax: +49 (0) 89 / 899 27-5439 investors@morphosys.com Dr. Claudia Gutjahr-Löser Mario Brkulj Director Corporate Communications PR Specialist Tel: +49 (0) 89 / 899 27-122 Tel: +49 (0) 89 / 899 27-454 Fax: +49 (0) 89 / 899 27-5122 Fax: +49 (0) 89 / 899 27-5454 gutjahr-loeser@morphosys.com brkulj@morphosys.com end of message, (c)DGAP 24.06.2004 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 240745 Jun 04